Clinical Trials
13 trialsNCT06191744 2026-05-06
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT03755804 2026-04-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT04510636 2024-03-22
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT01594229 2021-08-02
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Completed
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT01691807 2018-02-28
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Novartis
Phase 1 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT01657955 2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT00863850 2012-04-23
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed